CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3482-3489

  Zhu, Ziqiang ^a   Cuss, Steven M ^a   Singh, Vinod ^a,d   Gurusamy, Devikala ^a   Shoe, Jennifer L ^b   Leighty, Robert ^a   Bronte, Vincenzo ^c   Hurwitz, Arthur A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d SHRI MATA VAISHNO DEVI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; EPITOPE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; ANTIBODY AFFINITY; C57BL MOUSE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84942433156     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401571     Document Type: Article

References (32)

1. Kawai, K., and P. S. Ohashi. 1995. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374: 68-69.
2. Bullock, T. N., D. W. Mullins, T. A. Colella, and V. H. Engelhard. 2001. Manipulation of avidity to improve effectiveness of adoptively transferred CD8+ T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 167: 5824-5831.
3. Derby, M., M. Alexander-Miller, R. Tse, and J. Berzofsky. 2001. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166: 1690-1697.
4. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
5. Rosenberg, S. A. 2011. Cell transfer immunotherapy for metastatic solid cancer -what clinicians need to know. Nat. Rev. Clin. Oncol. 8: 577-585.
6. Brentville, V. A., R. L. Metheringham, B. Gunn, and L. G. Durrant. 2012. High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One 7: e41112.
7. Zhu, Z., V. Singh, S. K. Watkins, V. Bronte, J. L. Shoe, L. Feigenbaum, and A. A. Hurwitz. 2013. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73: 595-604.
8. Shafer-Weaver, K. A., S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, and A. A. Hurwitz. 2009. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 69: 6256-6264.
9. Ugel, S., A. Zoso, C. De Santo, Y. Li, I. Marigo, P. Zanovello, E. Scarselli, B. Cipriani, M. Oelke, J. P. Schneck, and V. Bronte. 2009. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 69: 9376-9384.
10. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17: 317-329.
11. Cordaro, T. A., K. E. de Visser, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2002. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 168: 651-660.
12. Bevan, M. J. 2004. Helping the CD8+ T-cell response. Nat. Rev. Immunol. 4: 595-602.
13. Zhu, J., and W. E. Paul. 2010. Heterogeneity and plasticity of T helper cells. Cell Res. 20: 4-12.
14. Wong, S. B., R. Bos, and L. A. Sherman. 2008. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J. Immunol. 180: 3122-3131.
15. Schietinger, A., M. Philip, R. B. Liu, K. Schreiber, and H. Schreiber. 2010. Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. J. Exp. Med. 207: 2469-2477.
16. Nakanishi, Y., B. Lu, C. Gerard, and A. Iwasaki. 2009. CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 462: 510-513. doi:10.1038/nature08511
17. Bos, R., and L. A. Sherman. 2010. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70: 8368-8377.
18. Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
19. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
20. Singh, V., Q. Ji, L. Feigenbaum, R. M. Leighty, and A. A. Hurwitz. 2009. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J. Immunother. 32: 129-139.
21. Watchmaker, P. B., J. A. Urban, E. Berk, Y. Nakamura, R. B. Mailliard, S. C. Watkins, S. M. van Ham, and P. Kalinski. 2008. Memory CD8+ T cells protect dendritic cells from CTL killing. J. Immunol. 180: 3857-3865.
22. Medema, J. P., D. H. Schuurhuis, D. Rea, J. van Tongeren, J. de Jong, S. A. Bres, S. Laban, R. E. Toes, M. Toebes, T. N. Schumacher, et al. 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194: 657-667.
23. Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff,W. W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
24. Church, S. E., S. M. Jensen, P. A. Antony, N. P. Restifo, and B. A. Fox. 2014. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur. J. Immunol. 44: 69-79.
25. Sotomayor, E. M., I. Borrello, E. Tubb, F. M. Rattis, H. Bien, Z. Lu, S. Fein, S. Schoenberger, and H. I. Levitsky. 1999. Conversion of tumor-specific CD4+ Tcell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
26. Cuenca, A., F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63: 9007-9015.
27. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
28. de Goër de Herve, M. G., A. Cariou, F. Simonetta, and Y. Taoufik. 2008. Heterospecific CD4 help to rescue CD8 T cell killers. J. Immunol. 181: 5974-5980.
29. Janssen, E. M., N. M. Droin, E. E. Lemmens, M. J. Pinkoski, S. J. Bensinger, B. D. Ehst, T. S. Griffith, D. R. Green, and S. P. Schoenberger. 2005. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88-93.
30. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
31. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
32. Bos, R., K. L. Marquardt, J. Cheung, and L. A. Sherman. 2012. Functional differences between low- and high-affinity CD8+ T cells in the tumor environment. OncoImmunology 1: 1239-1247.